ASTEX PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2011-01-01
- Employees
- 136
- Market Cap
- -
- Website
- http://www.astx.com
Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
- Conditions
- First Posted Date
- 2005-06-06
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT00113113
- Locations
- 🇺🇸
The Center for Cancer Care and Research, Saint Louis, Missouri, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer
- Conditions
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Registration Number
- NCT00005871
- Locations
- 🇺🇸
SuperGen, Incorporated, San Ramon, California, United States
Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas
- Conditions
- First Posted Date
- 2004-04-26
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Registration Number
- NCT00005870
- Locations
- 🇺🇸
SuperGen, Incorporated, San Ramon, California, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-04-13
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Registration Number
- NCT00005873
- Locations
- 🇺🇸
SuperGen, Incorporated, Dublin, California, United States
Nitrocamptothecin in Treating Patients With Metastatic Melanoma
- Conditions
- First Posted Date
- 2004-04-13
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Registration Number
- NCT00005875
- Locations
- 🇺🇸
SuperGen, Incorporated, Dublin, California, United States
Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas
- Conditions
- First Posted Date
- 2004-04-13
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Registration Number
- NCT00005874
- Locations
- 🇺🇸
SuperGen, Incorporated, Dublin, California, United States
Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-04-12
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Registration Number
- NCT00005872
- Locations
- 🇺🇸
SuperGen, Incorporated, Dublin, California, United States
Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- First Posted Date
- 2004-02-25
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Registration Number
- NCT00005869
- Locations
- 🇺🇸
SuperGen, Incorporated, Dublin, California, United States
Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer
- Conditions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Registration Number
- NCT00005877
- Locations
- 🇺🇸
SuperGen, Incorporated, Dublin, California, United States
Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
- Conditions
- First Posted Date
- 2003-12-17
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Registration Number
- NCT00005876
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States